What Is the Optimal Perioperative Treatment for Variant Subtypes of Bladder Cancer?

Area of Science:

• Oncology
• Pathology

Background:

• Urothelial carcinoma subtypes are classified using the 2022 World Health Organization (WHO) scheme.
• These cancers are generally considered high-risk, necessitating multidisciplinary care.

Purpose of the Study:

• To highlight the classification of urothelial carcinoma subtypes.
• To emphasize the need for improved therapeutic strategies for rare, non-responsive subtypes.

Main Methods:

• Review of the 2022 WHO classification for urothelial carcinoma.
• Analysis of current perioperative systemic therapy (neoadjuvant and adjuvant) responsiveness across subtypes.

Main Results:

• The 2022 WHO classification categorizes urothelial carcinoma subtypes.
• While some subtypes respond to perioperative systemic therapies, rare subtypes exhibit poor response.

Conclusions:

• Multidisciplinary evaluation is crucial for managing high-risk urothelial carcinoma subtypes.
• Development of novel therapies is essential for rare urothelial carcinoma subtypes unresponsive to current systemic treatments.